Co-founder and CEO of the Company with the vision to fight sepsis and antimicrobial resistance.
Advisor to the investment firm on diagnostic and medical device opportunities.
Head of the QIAstat Program at QIAGEN after the acquisition of STAT-Dx.
Co-founder and CEO of the Company from inception up to its trade sale to QIAGEN in 2018 ($192m).
Led the biomedical developments area in a Werfen Group company.